Regression of fibrous dysplasia in response to denosumab therapy: A report of two cases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 33912627.
- Also identified by DOI 10.1016/j.bonr.2021.101058 and PMC identifier 8066421.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
We present two patients with fibrous dysplasia who showed a decrease in lesional size and activity after denosumab therapy. Both patients also experienced a reduction in pain and bone turnover markers, which had not been accomplished during previous bisphosphonate therapy. These cases highlight the potential of denosumab to decrease lesional size in fibrous dysplasia. This finding has been reported in mice, but not in humans. Denosumab may be considered when bisphosphonates are not tolerated or not effective (enough), or in severe cases as neoadjuvant therapy to improve surgical possibilities and outcome. In addition, these results show that Na[<sup>18</sup> <i>F</i>]F PET-CT is suitable for detecting change in each fibrous dysplasia lesion distinctively.